HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ChemoCentryx (CCXI) Investors with Losses to Contact Its Attorneys Now, FDA Briefing Document Raises Serious Questions, Firm Investigating Possible Securities Law Violations
May 04, 2021 16:49 ET
|
Hagens Berman Sobol Shapiro LLP
SAN FRANCISCO, May 04, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges ChemoCentryx, Inc. (NASDAQ: CCXI) investors with significant losses to submit your losses now. The firm is investigating possible...